P

To study the oncologic and functional results of HIFU as a first-line treatment for localized prostate cancer.

Enrolment of patients between 2006 and 2011 for the first treatment against localized prostate cancer with HIFU (Integrated Imaging(®), EDAP-TMS, Vaulx-en-Velin, France).

The biochemical recurrence-free survival was calculated by using the Phoenix criterion (PSA>nadir+2ng/mL). The functional complications were assessed clinically and through standardised questionnaires.

The condition of 191 patients was assessed at a mean follow-up of 55. 5±22. 7 months. In 10,1% of the treatments, an incident during the medical procedure was observed with the volume of the prostate (P=0. 026) as risk factor. The overall survival, the survival and the metastatic free survival rate were respectively 89. 5%, 98. 4% and 97. 4%. The biochemical free survival rate for 5years was 87. 5%, 69% and 39% respectively for the low, medium and high-risk groups of d'Amico classification. Eighty-six percent of the patients with a PSA nadir≤0. 3ng/mL were relapse free at 5years. Whereas only 48% of the patients with a nadir>0. 3ng/mL did not. Only 17. 8% of the patients had a rescue treatment with an average delay of 31. 1 months. The urinary and sexual impairment was significant but 78. 1% of the patients were dry at the end of the study. The most common complication found in 18. 3% of the patients was the prostatic obstruction.

The oncologic and functional results of the HIFU seem similar to the other first-line treatments results and reveal that the HIFU is a therapeutic option for the treatment of prostate cancer in men over 70years.

5.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2015 Oct 14 [Epub ahead of print]

B Rouget, G Capon, J C Bernhard, G Robert, P Ballanger, G Pierquet, H Bensadoun, J-M Ferrière, G Pasticier

CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. , CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. , CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. , CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. , CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. , CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. , CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. , CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe